SQ Innovation today announced that results of the SUBCUT HF II trial of its product Lasix® ONYU, will be presented at Heart Failure 2026, the annual congress of the Heart Failure Association (HFA) of ...
Total hip arthroplasty leads to the best outcomes in the treatment of moderate-to-severe hip osteoarthritis, according to a ...
Global Phase 3, randomized, controlled trial comparing azenosertib to standard-of-care chemotherapy now enrollingASPENOVA designed as ...
MedPage Today on MSN
Game-Changer? Wegovy Cuts Heavy Drinking in Alcohol Addiction Trial
Findings come amid growing off-label prescribing of GLP-1 drugs for addiction ...
Review authors suggested guidelines to help in standardizing future lupus nephritis studies. Heterogeneity in lupus nephritis (LN) trial design substantially hinders interpretation of studied drugs’ ...
Tesamorelin can selectively reduce visceral fat, as demonstrated in RCTs. But the real story is what it reveals about ...
A postbiotic reduced allergic rhinitis symptoms in a clinical trial. Could microbiome therapies transform treatment? Read ...
Oxaliplatin-Based Versus Alkylating Agent in Neuroendocrine Tumors According to the O6-Methylguanine-DNA Methyltransferase Status: A Randomized Phase II Study (MGMT-NET) The median time post-HCT was ...
Background Patients undergoing thoracoscopic pulmonary resection are prone to moderate-to-severe acute postoperative pain, ...
Utility of the 70-Gene MammaPrint Assay for Prediction of Benefit From Extended Letrozole Therapy in the NRG Oncology/NSABP B-42 Trial Patients with advanced lung cancer reporting at least moderate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results